LS CancerDiag gets the patent granted in Brazil for its innovative DiagMMR® test.
The largest country in Latin America completes the already impressive patent portfolio of LS CancerDiag. Brazil brings the total count to 29 countries across the world.
As a result, the list of countries now covers all major markets in Europe, the Americas and Asia. The largest countries of the European Union are included, as well as the United States and Canada. They had granted the patents in 2018, following Russia, Japan, and China. However, Australia was leading the way all the way back in 2015. It was the first country to grant the patent to LS CancerDiag.
LS CancerDiag has successfully applied for patents and secured a very strong IP position globally. These efforts culminate with the patent granted in Brazil, underlining the strong IP strategy which the company has followed since its founding.
The latest developments emphasize the innovation power of LS CancerDiag with its predictive quantitative test. This supports the company’s ambition to improve Lynch syndrome detection at a global scale. The patent portfolio gives the company a unique position for expanding into new markets with DiagMMR®.
Click below to access the Press Release: